Wayne Pisano Purchases 30,000 Shares of Oncolytics Biotech (TSE:ONC) Stock

Oncolytics Biotech Inc. (TSE:ONC) Director Wayne Pisano bought 30,000 shares of the company’s stock in a transaction on Thursday, February 12th. The shares were bought at an average cost of C$1.16 per share, for a total transaction of C$34,800.00. Following the transaction, the director directly owned 288,306 shares in the company, valued at approximately C$334,434.96. This represents a 11.61% increase in their position.

Oncolytics Biotech Stock Performance

The company has a 50 day simple moving average of C$14.90 and a 200-day simple moving average of C$13.02. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. The firm has a market cap of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80. Oncolytics Biotech Inc. has a 1-year low of C$0.44 and a 1-year high of C$2.08.

Oncolytics Biotech (TSE:ONC) last released its quarterly earnings data on Wednesday, November 12th. The company reported C($0.14) earnings per share (EPS) for the quarter. As a group, equities analysts forecast that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.